Roivant and Pfizer unveil Priovant Therapeutics and ongoing registrational studies for oral brepocitinib in dermatomyositis and lupus

Priovant was established in September 2021 through a transaction between Roivant and Pfizer, in which Pfizer licensed oral and topical brepocitinib’s global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25% equity ownership interest in Priovant.

Brepocitinib is a potential first-in-class dual inhibitor of TYK2 and JAK1, a novel mechanism of action expected to potentially provide greater efficacy in multiple highly inflammatory autoimmune diseases, as compared to agents that inhibit either TYK2 or JAK1 alone. Priovant is developing oral brepocitinib as a franchise across multiple orphan and specialty autoimmune diseases with few approved therapies, high morbidity and mortality, and pathobiologies for which both TYK2 and JAK1 inhibition are expected to contribute to efficacy.

Oral brepocitinib is being evaluated in two ongoing registrational programs. Priovant recently initiated a single registrational PhaseIII study in dermatomyositis (VALOR). A large, global Phase IIb study in SLE, designed to serve as one of two registrational studies, is close to fully enrolled with data anticipated in 2H 2023..